This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Bifemelane
A multi-target nootropic marketed in Japan (as Celeport/Alnert) that enhances cholinergic and monoaminergic neurotransmission, prescribed for cerebrovascular dementia and cognitive impairment.
Benefits
What is Bifemelane?
Bifemelane (marketed as Alnert and Celeport in Japan) is a nootropic and neuroprotective drug that has been available in Japanese clinical practice since the mid-1980s. It is prescribed primarily for the treatment of cognitive impairment, particularly in elderly patients with cerebrovascular dementia, multi-infarct dementia, and age-related cognitive decline. What distinguishes Bifemelane from many other nootropics is its remarkably broad neuropharmacological profile: it simultaneously enhances cholinergic, dopaminergic, noradrenergic, and serotonergic neurotransmission, addressing multiple neurotransmitter deficiencies that contribute to cognitive dysfunction. Clinical trials in Japan, including studies by Kawamura et al. (1988) and Otomo et al. (1991), demonstrated significant improvements in cognitive function, daily living activities, and behavioural symptoms in patients with dementia when treated with Bifemelane at doses of 150-300 mg daily.
The multi-target mechanism of Bifemelane involves inhibition of monoamine oxidase (MAO) types A and B, enhancement of acetylcholine release, and direct effects on cerebral energy metabolism and blood flow. Research published in the Japanese Journal of Pharmacology and other domestic medical journals has shown that Bifemelane increases brain levels of dopamine, norepinephrine, serotonin, and acetylcholine simultaneously - a profile that theoretically addresses the multiple neurotransmitter deficiencies observed in aging and dementia. The MAO-inhibitory properties also give Bifemelane mild antidepressant-like effects, which can benefit the significant proportion of elderly dementia patients who experience concurrent depression. Studies by Nishibe et al. (1987) demonstrated that Bifemelane also enhances cerebral blood flow and glucose metabolism in ischaemic brain regions, providing a dual neuroprotective and neurotransmitter-enhancing mechanism. Despite decades of clinical use in Japan and a substantial body of Japanese-language research, Bifemelane has never been marketed or approved outside of Japan.
- Monoamine oxidase inhibition: Reversibly inhibits both MAO-A and MAO-B enzymes, reducing the degradation of dopamine, norepinephrine, serotonin, and other monoamine neurotransmitters, thereby increasing their synaptic availability
- Acetylcholine release enhancement: Promotes the release of acetylcholine from cholinergic nerve terminals in the cortex and hippocampus, supporting memory encoding, attention, and cognitive processing
- Dopaminergic enhancement: Through MAO-B inhibition and possible direct mechanisms, increases dopamine levels in the prefrontal cortex and striatum, supporting executive function, motivation, and reward processing
- Cerebral blood flow improvement: Increases regional cerebral blood flow, particularly in ischaemic areas, improving oxygen and glucose delivery to metabolically compromised brain tissue
- Mitochondrial function support: Enhances mitochondrial respiratory chain activity and ATP production in neurons, supporting the high energy demands of cognitive processing and providing protection against metabolic stress
- Standard clinical dose: 150 mg taken twice daily (300 mg total daily dose) as prescribed in Japanese clinical practice
- Starting dose: 150 mg once daily, increasing to 150 mg twice daily after 1-2 weeks based on tolerability
- Dose range: 150-300 mg daily, with most clinical trials using the 300 mg daily dose (150 mg morning and evening)
- Administration: Oral tablets taken after meals; morning and evening dosing is recommended to maintain stable plasma levels throughout the day
- Duration of treatment: Long-term use is common in Japanese clinical practice for chronic cognitive impairment, with treatment courses of 3-12 months evaluated in clinical trials
- Generally well-tolerated: Decades of clinical use in Japan have established a favourable safety profile, with most adverse effects being mild and manageable
- Common side effects: Nausea, abdominal discomfort, diarrhoea, rash, and headache are the most frequently reported adverse effects in clinical trials and post-marketing surveillance
- Hepatotoxicity reports: Rare cases of liver function abnormalities have been reported; periodic monitoring of liver function tests is recommended during treatment
- MAO inhibitor interactions: Although Bifemelane's MAO inhibition is relatively mild, caution is warranted with concurrent use of other MAO inhibitors, sympathomimetic amines, serotonergic drugs, and tyramine-rich foods
- Blood pressure monitoring: The combination of MAO inhibition and noradrenergic enhancement warrants monitoring for hypertensive episodes, particularly in patients with pre-existing hypertension
- Limited availability: Available only in Japan through prescription; not approved by the FDA, EMA, or other Western regulatory agencies
Natural Sources & Forms
- Kawamura et al. (1988): Clinical trial of Bifemelane in patients with cerebrovascular dementia demonstrating cognitive and functional improvements, published in Japanese Clinical Pharmacology and Therapeutics
- Otomo et al. (1991): Multi-centre double-blind study of Bifemelane in dementia patients, published in the Japanese Journal of Clinical Pharmacology and Therapeutics
- Nishibe et al. (1987): Pharmacological study demonstrating Bifemelane's effects on cerebral blood flow and glucose metabolism in the Japanese Journal of Pharmacology
- Japanese PMDA product information: Official prescribing information for Alnert (Bifemelane) tablets as approved by the Japanese Pharmaceuticals and Medical Devices Agency
- Nagatsu and Yoshida (1988): Review of Bifemelane's monoamine oxidase inhibitory activity and neuroprotective mechanisms in Neuroscience Letters
Frequently Asked Questions
A multi-target nootropic marketed in Japan (as Celeport/Alnert) that enhances cholinergic and monoaminergic neurotransmission, prescribed for cerebrovascular dementia and cognitive impairment.
The key benefits of Bifemelane include: Cognitive Enhancement, Energy, Focus, Memory, Mood, Motivation.
Monoamine oxidase inhibition: Reversibly inhibits both MAO-A and MAO-B enzymes, reducing the degradation of dopamine, norepinephrine, serotonin, and other monoamine neurotransmitters, thereby increasing their synaptic availability Acetylcholine release enhancement: Promotes the release of acetylcholine from cholinergic nerve terminals in the cortex and hippocampus, supporting memory encoding, attention, and cognitive processing Dopaminergic enhancement: Through MAO-B inhibition and possible direct mechanisms, increases dopamine levels in the prefrontal cortex and striatum, supporting executive function, motivation, and reward processing Cerebral blood flow improvement: Increases regional cerebral blood flow, particularly in ischaemic areas, improving oxygen and glucose delivery to metabolically compromised brain tissue Mitochondrial function support: Enhances mitochondrial respiratory chain activity and ATP production in neurons, supporting the high energy demands of cognitive processing and providing protection against metabolic stress
Standard clinical dose: 150 mg taken twice daily (300 mg total daily dose) as prescribed in Japanese clinical practice Starting dose: 150 mg once daily, increasing to 150 mg twice daily after 1-2 weeks based on tolerability Dose range: 150-300 mg daily, with most clinical trials using the 300 mg daily dose (150 mg morning and evening) Administration: Oral tablets taken after meals; morning and evening dosing is recommended to maintain stable plasma levels throughout the day Duration of treatment: Long-term use is common in Japanese clinical practice for chronic cognitive impairment, with treatment courses of 3-12 months evaluated in clinical trials
Generally well-tolerated: Decades of clinical use in Japan have established a favourable safety profile, with most adverse effects being mild and manageable Common side effects: Nausea, abdominal discomfort, diarrhoea, rash, and headache are the most frequently reported adverse effects in clinical trials and post-marketing surveillance Hepatotoxicity reports: Rare cases of liver function abnormalities have been reported; periodic monitoring of liver function tests is recommended during treatment MAO inhibitor interactions: Although Bifemelane's MAO inhibition is relatively mild, caution is warranted with concurrent use of other MAO inhibitors, sympathomimetic amines, serotonergic drugs, and tyramine-rich foods Blood pressure monitoring: The combination of MAO inhibition and noradrenergic enhancement warrants monitoring for hypertensive episodes, particularly in patients with pre-existing hypertension Limited availability: Available only in Japan through prescription; not approved by the FDA, EMA, or other Western regulatory agencies
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!